55
Participants
Start Date
June 13, 2017
Primary Completion Date
February 16, 2020
Study Completion Date
June 29, 2023
Durvalumab
On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
New York University Laura and Isaac Perlmutter Cancer Center, New York
Hillman Cancer Center Research Pavilion, Pittsburgh
Fox Chase Cancer Center, Philadelphia
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Virginia Cancer Specialists, Fairfax
Winship Cancer Institute of Emory University, Atlanta
University of Miami Hospital, Miami
St. Joseph Mercy Hospital, Ann Arbor
Aurora Cancer Center, Wauwatosa
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park
NorthShore University HealthSystem, Evanston
University of Chicago Medical Center, Chicago
Washington University in St Louis, St Louis
UTSW Medical Center, Dallas
University of Colorado, Anschutz Cancer Pavilion, Aurora
Ronald Reagan UCLA Medical Center, Los Angeles
University San Diego Moores Cancer Center, La Jolla
Stanford Cancer Institute, Stanford
University of Washington Seattle Cancer Care Alliance, Seattle
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
AstraZeneca
INDUSTRY
PrECOG, LLC.
OTHER